February 18, 2013 / 6:21 AM / in 5 years

Roche, Chiasma ink deal on gland disorder treatment

ZURICH, Feb 18 (Reuters) - Swiss drugmaker Roche said on Monday it would work with privately held Chiasma to develop and market a treatment for growth hormone disorders in a deal worth almost $600 million in upfront and milestone payments.

The companies will work on the development Octreolin, an oral form of a growth hormone treatment now only sold in injections. Octreolin is currently in a late stage trial for the treatment of a condition caused by excessive growth hormone.

Roche will make an upfront payment of $65 million to Chiasma, further milestone payments of up to $530 million and double digit royalties on net sales of Octreolin.

Reporting by Martin de Sa'Pinto

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below